Haystack MRD™ prioritizes truncal somatic mutations those mutations that are present at the initial formation of a tumor or the trunk of the cancer evolutionary tree

One of the most critical differentiators among minimal residual disease MRD tests is whether they are tumor informed or whether they are tumor naive

The landmark DYNAMIC study is the first prospective randomized interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy